Αποτελέσματα Αναζήτησης
6 Αυγ 2024 · Mycoplasma pneumoniae is one of the smallest free-living organisms and a common bacterial respiratory tract pathogen. Upper respiratory tract infections and acute bronchitis are the most common manifestations of M. pneumoniae infection, but pneumonia can also occur.
Learn about the drugs of choice for treating mycoplasmal pneumonia, a common cause of community-acquired pneumonia. Find out how to overcome macrolide resistance and when to use tetracyclines or fluoroquinolones.
25 Οκτ 2022 · A macrolide or tetracycline antibiotic is usually effective as first-line treatment of mycoplasma infections in both uncomplicated and more severe community-acquired pneumonia. Fluoroquinolones may be effective as second-line treatment if previous antibiotics fail.
16 Ιαν 2023 · Treatment of M pneumoniae includes macrolides, doxycycline, or fluoroquinolones. Azithromycin is the most frequently used antibiotic and is usually prescribed for 5 days (500 mg for the first dose, followed by 250 mg daily for 4 days).
27 Δεκ 2023 · Most Mycoplasma pneumoniae infections are self-limiting. Healthcare providers routinely treat pneumonia caused by M. pneumoniae with antibiotics. Some strains of M. pneumoniae may be resistant to macrolides.
INTRODUCTION. Mycoplasma pneumonia is a common respiratory pathogen that produces diseases of varied severity ranging from mild upper respiratory tract infection to severe atypical pneumonia.
14 Σεπ 2015 · Mycoplasma pneumoniae has emerged as leading causative agent of CAP in some region, and the abrupt increasing resistance to macrolide that widely used for management of M. pneumoniae has reached to the level that it often leads to treatment failures. Objective.
